SE9402241L - Inhibitor - Google Patents

Inhibitor

Info

Publication number
SE9402241L
SE9402241L SE9402241A SE9402241A SE9402241L SE 9402241 L SE9402241 L SE 9402241L SE 9402241 A SE9402241 A SE 9402241A SE 9402241 A SE9402241 A SE 9402241A SE 9402241 L SE9402241 L SE 9402241L
Authority
SE
Sweden
Prior art keywords
pct
sec
date
pub
integrase
Prior art date
Application number
SE9402241A
Other languages
English (en)
Other versions
SE504289C2 (sv
SE9402241D0 (sv
Inventor
Jan Olof Einar Bergman
Original Assignee
Leif J I Lundblad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leif J I Lundblad filed Critical Leif J I Lundblad
Priority to SE9402241A priority Critical patent/SE504289C2/sv
Publication of SE9402241D0 publication Critical patent/SE9402241D0/sv
Priority to IL11420195A priority patent/IL114201A/xx
Priority to US08/765,263 priority patent/US5866575A/en
Priority to PCT/SE1995/000747 priority patent/WO1996000067A1/en
Priority to ES95923639T priority patent/ES2166400T3/es
Priority to AU28121/95A priority patent/AU2812195A/en
Priority to EP95923639A priority patent/EP0760662B1/en
Priority to DE69523450T priority patent/DE69523450T2/de
Priority to APAP/P/1995/000751A priority patent/AP604A/en
Publication of SE9402241L publication Critical patent/SE9402241L/sv
Publication of SE504289C2 publication Critical patent/SE504289C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9402241A 1994-06-23 1994-06-23 Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras SE504289C2 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9402241A SE504289C2 (sv) 1994-06-23 1994-06-23 Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
IL11420195A IL114201A (en) 1994-06-23 1995-06-18 Pharmaceutical HIV integrase inhibiting compositions containing 6-aminoalkyl-6H-indolo-[2,3-b]quinoxalines
DE69523450T DE69523450T2 (de) 1994-06-23 1995-06-19 Inhibitor
ES95923639T ES2166400T3 (es) 1994-06-23 1995-06-19 Inhibidor.
PCT/SE1995/000747 WO1996000067A1 (en) 1994-06-23 1995-06-19 Inhibitor
US08/765,263 US5866575A (en) 1994-06-23 1995-06-19 Method of inhibiting HIV integrase
AU28121/95A AU2812195A (en) 1994-06-23 1995-06-19 Inhibitor
EP95923639A EP0760662B1 (en) 1994-06-23 1995-06-19 Inhibitor
APAP/P/1995/000751A AP604A (en) 1994-06-23 1995-06-21 Substituted indoloquinoxalines and their use as HIV integrase inhibiting compositions.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402241A SE504289C2 (sv) 1994-06-23 1994-06-23 Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras

Publications (3)

Publication Number Publication Date
SE9402241D0 SE9402241D0 (sv) 1994-06-23
SE9402241L true SE9402241L (sv) 1995-12-24
SE504289C2 SE504289C2 (sv) 1996-12-23

Family

ID=20394513

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402241A SE504289C2 (sv) 1994-06-23 1994-06-23 Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras

Country Status (9)

Country Link
US (1) US5866575A (sv)
EP (1) EP0760662B1 (sv)
AP (1) AP604A (sv)
AU (1) AU2812195A (sv)
DE (1) DE69523450T2 (sv)
ES (1) ES2166400T3 (sv)
IL (1) IL114201A (sv)
SE (1) SE504289C2 (sv)
WO (1) WO1996000067A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
SE504862C2 (sv) * 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
US6465466B1 (en) 1995-12-22 2002-10-15 Leif J. I. Lundblad Uses of indolo-2 [2,3b] -quinoxalines
SE9704723D0 (sv) * 1997-12-17 1997-12-17 Leif J I Lundblad Ligands
SE516133C2 (sv) * 1999-02-25 2001-11-19 Lundblad Leif J I Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation
EP4164616A1 (en) * 2020-06-10 2023-04-19 Cyxone AB Oral formulation comprising a crystalline form of rabeximod

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (sv) * 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
SE504862C2 (sv) * 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler

Also Published As

Publication number Publication date
US5866575A (en) 1999-02-02
AP604A (en) 1997-07-21
DE69523450T2 (de) 2002-05-16
SE504289C2 (sv) 1996-12-23
ES2166400T3 (es) 2002-04-16
AP9500751A0 (en) 1995-07-31
IL114201A0 (en) 1995-10-31
IL114201A (en) 2000-11-21
WO1996000067A1 (en) 1996-01-04
EP0760662A1 (en) 1997-03-12
EP0760662B1 (en) 2001-10-24
SE9402241D0 (sv) 1994-06-23
AU2812195A (en) 1996-01-19
DE69523450D1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
FI961506A0 (sv) Distamycin A analoger som antitumöriska eller antivirala medel
ATE200669T1 (de) 4-hydroxy-benzopyran-2-one und 4-hydroxy- zykloalkyl(b) - pyran--2-one verwendbarfuer die behandlung von retroviralen infectionen
ATE167476T1 (de) Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
BR9611175A (pt) Compostos ou suas composições e uso dos mesmo
KR0179637B1 (en) Diaromatic substituted compounds as anti-hiv-1 agents
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ATE196765T1 (de) Dihydrobenzofurane
NO962286D0 (no) N-substituerte azabicykloalkanderivater som neuroleptika etc.
ITMI931780A1 (it) Tropil 7-azaindolil-3-carbossiamidi
ES2153975T3 (es) Derivados de pirimidona con actividad antifungica.
ID22042A (id) Benzonaftiridin sebagai pengobatan cabang tenggorokan
FI964772A0 (sv) (a)-annellerade pyrrolderivat och deras användning i farmacin
DE59507755D1 (de) Dipeptidische p-amidinobenzylamide mit n-terminalen sulfonyl- bzw. aminosulfonylresten
FI973221A0 (sv) 1-aryl-2-acylammo-etanföreningar och användning därav som neurokininantagonister, särskilt som neurokinin 1 antagonister
DK0775135T3 (da) N-Substituerede 3-azabicyclo[3.2.0]heptanderivater som neuroleptika
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
MX9301112A (es) Derivados de indol.
SE9402241D0 (sv) Inhibitor
NO923226L (no) Nytt beta-fenylisoserinderivat, dets fremstilling og anvendelse
DK0696278T3 (da) Herbicidtvirkende substituerede 1-phenyl- eller 1-pyridinylbenzotriazoler
DE69522332T2 (de) 1,4-dihydropyridine als bradykinin antagonisten
DK0668852T3 (da) Substituerede orthoethenylphenyleddikesyrederivater
ATE291904T1 (de) 2,4-dichlorbenzylalkohol und amylmetakresol gegen hiv-infektion
DE59409923D1 (de) Substituierte aminoalkylaminopyridine
EA200200491A1 (ru) Замещенные 1,2,3,4,5,6-гексагидро-2,6-метано-3-бензазоцины и их применение в качестве лекарственных средств

Legal Events

Date Code Title Description
NUG Patent has lapsed